It's been a great first half of the #AI in Drug & Biological Product Development hybrid public workshop in front of a full house at U.S. FDA. There's still more to come, so don't miss out on the afternoon sessions! bit.ly/AIpublicworksh…

Very insightful sessions and questions so far! CTTI U.S. FDA #AIinResearch #AIRegulations #IRB #Ethics

Our founder and CEO, Charles Fisher, was featured in an Endpoints News article covering yesterday's U.S. FDA/CTTI workshop on "Artificial Intelligence in Drug & Biological Product Development." 🚀 Read it here: endpts.com/fda-grapples-w…

Achieving representative clinical trials in the U.S. requires coordinated action. ACRP recognizes Multi-Regional Clinical Trials Center, CTTI, Milken Institute, and National Academies for developing a national plan to inspire system-level change in improving trial representation. bit.ly/3YAOOyO

REMINDER: Today is the last day to submit your application to become a member of the PEC. The application portal will close tonight at 11:59 p.m. EDT. Don't miss your chance to make a difference! bit.ly/4eVuhuw

Our CEO, Luca Emili, was a panelist at the U.S. FDA CTTI AI Workshop alongside Michael Lingzhi Li (Harvard Business School) and Subha Madhavan (Pfizer Inc.). Discover how we’re revolutionizing drug development! 🔗Read more here: linkedin.com/posts/insilico… #AI #FDA #DrugDevelopment

The FDA Patient Affairs and #CTTI PEC application process closed on August 8 at 11:59 p.m. ET. The application review process will take a minimum of two months. Thank you to all who applied to become a member! #patientengagement

Discover how Lindus Health revolutionized #clinicaltrials using #CTTI’s #AACT Database! From risk protection to #AI-driven protocol generation, learn about the transformative power of data-driven decisions in #clinicalresearch. bit.ly/LindusHealthcs

By leveraging #CTTI’s #AACT Database, Lindus Health drastically cut trial start-up times & improved outcome predictability. Explore their journey towards more efficient & robust #clinicaltrial designs. bit.ly/LindusHealthcs

“We went from protocol synopsis to first patient in 6 weeks!” Lindus Health’s use of #AACT Database sets a new standard in #clinicaltrials. Learn how data-driven insights can enhance trial success & speed. bit.ly/LindusHealthcs

The Patient Engagement Collaborative (PEC) is an ongoing, shared setting in which the patient community (PEC members), U.S. FDA, and CTTI discuss topics for improving communication, education, and patient engagement. fda.gov/patients/learn…

NOW AVAILABLE: Hybrid public workshop recording on #AI in Drug & Biological Product Development. U.S. FDA & #CTTI were proud to collab on this workshop of >9,000 registrants & convened experts in AI including academia, drug sponsors & technology orgs. bit.ly/3XgpsFu

Missed out on the hybrid public workshop convened by the U.S. FDA and #CTTI on #AI in Drug and Biological Product Development? Recording now available! bit.ly/3XgpsFu

“If we really want #AI to have an impact on #drugdevelopment, we’re going to need to invite more AI researchers into the drug development process.” - Charles Fisher at the U.S. FDA / CTTI workshop, ‘AI in Drug & Biological Product Development.’ Watch the recording here:

ICYMI: Learn more about guiding principles for the responsible use of #AI in the development of safe and effective drugs and biological products. View the recording & slides for #CTTI & U.S. FDA’s hybrid public workshop. bit.ly/3XgpsFu

Collaboration is key! Parent Project Muscular Dystrophy (PPMD)’s use of #CTTI’s Chevron Diagram has led to 7 #patient preference studies, proving that patient-centered research accelerates progress. Learn more at bit.ly/PPMDcs

Patient voices must be heard! Parent Project Muscular Dystrophy (PPMD) uses #CTTI tool to embed #patient insights across every stage of #Duchenne research, ensuring that drug development truly reflects what matters to patients. bit.ly/PPMDcs

We and CTTI host the Patient Engagement Collaborative (PEC), which is a forum of 16 patient community members, who discuss and provide considerations for new strategies to enhance patient engagement, transparency, and communication at U.S. FDA.fda.gov/patients/learn…

Diverse clinical trials = better, more accurate research. #CTTI’s Sabrena Mervin-Blake sat down w/ Xtalks Webinars to talk strategies for boosting inclusivity in #clinicaltrials. From partnerships to accountability, here’s how CTTI is driving change. Read more: bit.ly/3B7poz5

Curious how we could transform clinical evidence generation to better align with #healthcare demands? A new paper by #CTTI, Duke Clinical Research Institute, Duke-Margolis & Protas explores approaches to modernizing #clinicaltrials infrastructure. Read more: bit.ly/47wqdxA BMC